Pipeline

Overview

The drug pipeline of Priavoid is composed of 7 compounds at various stages of pharmaceutical development within 6 diseases:

Alzheimer’s disease
Neuropathic pain
Amyotrophic lateral sclerosis
Tauopathies
Huntington’s disease
Parkinson’s disease

PRI-002

is the most advanced drug in our pipeline for the causal treatment of Alzheimer’s disease (AD).

Thus, PRI-002 has three unique selling propositions (USPs):

New mechanism of action
Specific elimination of toxic Aβ oligomers

New drug substance class
Synthetic all-D-peptide

Oral drug administration
Protease resistant

Intervention Strategy

Priavoid developed a completely new therapeutic strategy for the causal treatment of Alzheimer’s disease. The orally available D-peptide PRI-002 permeates the blood-brain barrier effectively, does not interfere with formation or clearance of non-toxic Aß monomers, but specifically eliminates cytotoxic Aß-oligomers.

Partnering

Partnering is a key component of Priavoids strategy

Learn more